Evidence map›Paper›PMID 40598306›Full record

ArticleBMC biotechnology2025

An engineered self-cleavage fusion system for the production of chimaera spider silk proteins.

Yongqin Su, Ke Zheng, Cheng Cheng

Abstract read
In one paragraph

Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yongqin Su2011 College, Nanjing Tech University, No. 30 Puzhu South Road, Nanjing, 211816, China.
Ke ZhengBiomass Molecular Engineering Center and Department of Materials Science and Engineering, School of Forestry and Landscape Architecture, Anhui Agricultural University, Hefei, Anhui, 230036, China.
Cheng ChengSchool of Pharmaceutical Sciences, Nanjing Tech University, No. 30 Puzhu South Road, Nanjing, 211816, China. cheng2@njtech.edu.cn.

Funding

Jiangsu Provincial Association for Science and Technology Youth Talent Support Project TJ-2023-021National Natural Science Foundation Youth Fund 22308159Natural Science Foundation of Jiangsu Province BK20220335
6 · The paper itself

Abstract

backgroundSpidroins are well-known for their exceptional mechanical properties, which have inspired extensive research and applications across various fields. Large-scale production of spidroin continues to face major challenges due to the complexity involved in inducing host organisms to express full-length spidroins. This process requires advanced techniques and has issues such as plasmid instability and potential misfolding.

resultsIn this study, we developed a novel expression system by combining a fusion tag with a self-cleavage intein, enabling the convenient expression of three chimeric spidroins with varying numbers of repetitive units. After optimising expression conditions, NT2RepCT, NT4RepCT and NT6RepCT spidroins were obtained in soluble form, with yields of 266, 135 and 125 mg/L, respectively. All three spidroins exhibited an increased β-sheet content with increased numbers of repetitive units during transition from soluble to dry state. In terms of nanofibril morphologies, the self-assemblies of NT4RepCT and NT6RepCT closely resemble those of native silk proteins.

conclusionThis study can serve as a reference for preparation of high-performance spider silk materials and soluble expression of proteins, such as collagen, and as a foundation for preparation of other structurally complex polymer materials.

Indexed as

FibroinsProtein EngineeringRecombinant Fusion ProteinsSpidersAnimalsEscherichia coliInteinsFibroinsRecombinant Fusion ProteinsChimeric spidroinFusion strategySelf-assemblySelf-cleavage intein

Identifiers

PMID40598306
PMCPMC12218096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.